RT @bella_mehta: Long term data on Canakinumab - IL-1B antibody in #AOSD @EULAR2023 25 pts with persistent disease activ

Social Author Image
https://pbs.twimg.com/profile_images/1248272740831735809/C0SA-iJf.jpg
Tweet Author
bella_mehta
Social Author Name
Bella Mehta
Tweet Content
Long term data on Canakinumab - IL-1B antibody in #AOSD @EULAR2023 25 pts with persistent disease activity, f/u 12 mths, remission in all but 2 pts. Improved parameters as below :- @rheumnow abst#OP0257 https://t.co/7jKTp87FlX
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.